IBT B Stock Overview
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr87.40 |
| 52 Week High | kr107.00 |
| 52 Week Low | kr41.30 |
| Beta | 1.01 |
| 1 Month Change | 14.40% |
| 3 Month Change | -15.56% |
| 1 Year Change | 80.21% |
| 3 Year Change | -12.77% |
| 5 Year Change | -51.44% |
| Change since IPO | -17.93% |
Recent News & Updates
Recent updates
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans
Apr 03
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation
Sep 16We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
May 11We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
Sep 23We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely
Apr 07We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Dec 15We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 25We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
May 06Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)
Feb 07Shareholder Returns
| IBT B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 5.3% | -6.7% | -0.7% |
| 1Y | 80.2% | 60.6% | 8.7% |
Return vs Industry: IBT B exceeded the Swedish Pharmaceuticals industry which returned 65.2% over the past year.
Return vs Market: IBT B exceeded the Swedish Market which returned 8.1% over the past year.
Price Volatility
| IBT B volatility | |
|---|---|
| IBT B Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IBT B has not had significant price volatility in the past 3 months.
Volatility Over Time: IBT B's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| IBT B fundamental statistics | |
|---|---|
| Market cap | kr1.18b |
| Earnings (TTM) | -kr123.07m |
| Revenue (TTM) | kr77.00k |
Over9,999x
P/S Ratio-9.6x
P/E RatioIs IBT B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT B income statement (TTM) | |
|---|---|
| Revenue | kr77.00k |
| Cost of Revenue | kr0 |
| Gross Profit | kr77.00k |
| Other Expenses | kr123.15m |
| Earnings | -kr123.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -9.14 |
| Gross Margin | 100.00% |
| Net Profit Margin | -159,828.57% |
| Debt/Equity Ratio | 0% |
How did IBT B perform over the long term?
See historical performance and comparison